Pharmacokinetics of tigecycline in turkeys following different routes of administration.

Abstract

The aim of this research had been to determine the pharmacokinetics of tigecycline (TIG) in turkey after intravenous (i.v.), intramuscular (i.m.), subcutaneous (s.c.), and oral (p.o.) administration at a dose of 10mg/kg. TIG concentrations in plasma were determined using high-performance liquid chromatography with tandem mass spectrometry. Mean concentrations of TIG in turkey plasma in the i.v. group were significantly higher than concentrations of this drug obtained after using the other administration routes. No significant differences were demonstrated in respect to the concentrations achieved after i.m. and s.c. administration. The bioavailability of TIG after i.m., s.c., and p.o. administration was 32.59±5.99%, 34.91±9.62%, and 0.97±0.57%, respectively. Values of half-life in the elimination phase were 23.49±6.51hr, 25.42±4.42hr, and 26.62±5.19hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92±1.41hr, 19.62±2.82hr, and 17.55±2.59hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85±5.71L/kg, 14.68±2.56L/kg, and 15.37±3.00L/kg in i.v., i.m., and s.c. groups, respectively. Because TIG is not absorbed from the gastrointestinal tract in turkeys to a clinically significant degree, this drug given p.o. could find application in commercial turkey farms only to treat gastrointestinal tract infections.